Total Payments
$10,134
2024 Payments
$2,521
Companies
39
Transactions
777
Medicare Patients
858
Medicare Billing
$89,355
Payment Breakdown by Category
Food & Beverage$9,971 (98.4%)
Education$163.21 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,971 | 765 | 98.4% |
| Education | $163.21 | 12 | 1.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $2,064 | 155 | $0 (2024) |
| ABBVIE INC. | $1,781 | 174 | $0 (2024) |
| Lilly USA, LLC | $1,363 | 116 | $0 (2024) |
| PFIZER INC. | $442.76 | 29 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $439.82 | 30 | $0 (2024) |
| Amgen Inc. | $425.45 | 39 | $0 (2024) |
| Dexcom, Inc. | $390.68 | 24 | $0 (2024) |
| GlaxoSmithKline, LLC. | $343.38 | 24 | $0 (2023) |
| Amarin Pharma Inc. | $305.82 | 20 | $0 (2022) |
| Janssen Pharmaceuticals, Inc | $276.42 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,521 | 194 | Novo Nordisk Inc ($504.80) |
| 2023 | $3,299 | 254 | Novo Nordisk Inc ($619.26) |
| 2022 | $2,406 | 186 | Novo Nordisk Inc ($565.14) |
| 2021 | $1,908 | 143 | AbbVie Inc. ($376.46) |
All Payment Transactions
777 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $28.21 | General |
| Category: Diabetes | ||||||
| 12/18/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $10.38 | General |
| Category: Diabetes | ||||||
| 12/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $3.06 | General |
| Category: Diabetes | ||||||
| 12/06/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Obesity | ||||||
| 12/04/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $14.43 | General |
| Category: PAIN | ||||||
| 12/04/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $12.75 | General |
| Category: Gastroenterology | ||||||
| 12/03/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $8.80 | General |
| Category: NEUROSCIENCE | ||||||
| 12/02/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $17.09 | General |
| Category: Cardio-renal | ||||||
| 11/21/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $6.29 | General |
| Category: PAIN | ||||||
| 11/18/2024 | Lilly USA, LLC | — | Education | In-kind items and services | $6.65 | General |
| 11/16/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $6.73 | General |
| Category: Cardio-renal | ||||||
| 11/13/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $8.82 | General |
| Category: Gastroenterology | ||||||
| 11/12/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $12.31 | General |
| Category: Diabetes | ||||||
| 11/08/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $18.68 | General |
| Category: Obesity | ||||||
| 11/07/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $8.69 | General |
| Category: Diabetes | ||||||
| 11/06/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: UROLOGY | ||||||
| 11/05/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $18.88 | General |
| Category: Diabetes | ||||||
| 11/05/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $8.21 | General |
| Category: NEUROSCIENCE | ||||||
| 11/04/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: PAIN | ||||||
| 10/30/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $4.42 | General |
| Category: Cardio-renal | ||||||
| 10/21/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $8.48 | General |
| Category: NEUROSCIENCE | ||||||
| 10/17/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: Diabetes | ||||||
| 10/10/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $26.59 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 246 | 544 | $45,107 | $25,218 |
| 2022 | 9 | 351 | 834 | $66,381 | $36,303 |
| 2021 | 8 | 261 | 645 | $42,367 | $27,833 |
Total Patients
858
Total Services
2,023
Medicare Billing
$89,355
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 89 | 215 | $19,428 | $9,885 | 50.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 80 | 143 | $18,150 | $9,621 | 53.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 53 | 53 | $6,706 | $5,568 | 83.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 13 | 22 | $370.03 | $137.25 | 37.1% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 11 | 111 | $452.88 | $6.97 | 1.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 123 | 304 | $27,555 | $14,291 | 51.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 97 | 191 | $24,596 | $13,204 | 53.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 53 | 53 | $6,836 | $5,218 | 76.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 28 | $2,088 | $1,313 | 62.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 14 | 14 | $2,281 | $1,182 | 51.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 14 | 14 | $1,656 | $728.08 | 44.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 15 | 36 | $504.72 | $319.99 | 63.4% |
| 81003 | Automated urinalysis test | Office | 2022 | 13 | 14 | $210.00 | $31.06 | 14.8% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2022 | 11 | 180 | $653.20 | $16.50 | 2.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 108 | 232 | $19,827 | $12,738 | 64.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 40 | 151 | $10,788 | $7,139 | 66.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 44 | 53 | $6,590 | $4,317 | 65.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 16 | 16 | $1,944 | $1,754 | 90.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 13 | $1,201 | $883.74 | 73.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 12 | 12 | $1,364 | $742.60 | 54.5% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 16 | 28 | $366.24 | $243.94 | 66.6% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2021 | 13 | 140 | $287.00 | $14.95 | 5.2% |
About Kacy Ramirez
Kacy Ramirez is a Family healthcare provider based in Corpus Christi, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/30/2021. The National Provider Identifier (NPI) number assigned to this provider is 1912585142.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Kacy Ramirez has received a total of $10,134 in payments from pharmaceutical and medical device companies, with $2,521 received in 2024. These payments were reported across 777 transactions from 39 companies. The most common payment nature is "Food and Beverage" ($9,971).
As a Medicare-enrolled provider, Ramirez has provided services to 858 Medicare beneficiaries, totaling 2,023 services with total Medicare billing of $89,355. Data is available for 3 years (2021–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Family
- Location Corpus Christi, TX
- Active Since 03/30/2021
- Last Updated 03/30/2021
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1912585142
Products in Payments
- Ozempic (Drug) $1,166
- MOUNJARO (Drug) $692.75
- UBRELVY (Drug) $602.03
- NURTEC ODT (Drug) $536.26
- QULIPTA (Drug) $515.72
- Kerendia (Drug) $439.82
- Rybelsus (Drug) $384.46
- Otezla (Drug) $344.17
- Dexcom G6 Transmitter (Medical Supply) $324.02
- Vascepa (Drug) $305.82
- XARELTO (Drug) $276.42
- Wegovy (Drug) $267.91
- XIFAXAN (Drug) $242.35
- VRAYLAR (Drug) $235.43
- QUVIVIQ (Drug) $230.21
- TRELEGY ELLIPTA (Drug) $228.73
- JARDIANCE (Drug) $204.83
- Saxenda (Drug) $194.11
- EMGALITY (Drug) $186.68
- LINZESS (Drug) $170.58
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Corpus Christi
Mrs. Katie Montgomery, Fnp-C, FNP-C
Family — Payments: $26,748
Family $26,748
Anna Wagner, Fnp, FNP
Family — Payments: $19,396
Family $19,396
Stacey Sanchez, Np, NP
Family — Payments: $15,063
Family $15,063
Mfon Ofong, Np, NP
Family — Payments: $11,690
Family $11,690
Jessica Gagnon, Cfnp, CFNP
Family — Payments: $11,183
Family $11,183
Flavia Lopez, Np-C, NP-C
Family — Payments: $10,563
Family $10,563